BU-32: a novel proteasome inhibitor for breast cancer

to related objects

Location: Deutsche Nationalbibliothek Frankfurt am Main

ISSN: 1465-542X

Extent: Online-Ressource

Language: Englisch

Notes: online resource.

Bibliographic citation: BU-32: a novel proteasome inhibitor for breast cancer ; volume:11 ; number:5 ; day:12 ; month:10 ; year:2009 ; pages:1-13 ; date:10.2009
Breast cancer research ; 11, Heft 5 (12.10.2009), 1-13, 10.2009

Creator: Agyin, Joseph K.

Contributor: Santhamma, Bindu
Nair, Hareesh B.
Roy, Sudipa S.
Tekmal, Rajeshwar R.
SpringerLink (Online service)

DOI: 10.1186/bcr2411

URN: urn:nbn:de:1111-201603245741

Rights: Der Zugriff auf das Objekt ist unbeschränkt möglich.

Last update: 14.08.2025, 11:01 AM CEST

Data provider

This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.

Show original at data provider

Associated

Agyin, Joseph K.
Santhamma, Bindu
Nair, Hareesh B.
Roy, Sudipa S.
Tekmal, Rajeshwar R.
SpringerLink (Online service)

Other Objects (12)

Repurposing proteasome inhibitors for improved treatment of triple-negative breast cancer

Proteasome inhibitors against amelanotic melanoma

Gastrointestinal toxicities of proteasome inhibitor therapy

Hochschulschrift

Characterisation and optimisation of 20S proteasome inhibitors

Hochschulschrift

Characterisation and optimisation of 20S proteasome inhibitors

Suberoyl bis-hydroxamic acid enhances cytotoxicity induced by proteasome inhibitors in breast cancer cells

A novel role of lysophosphatidic acid (LPA) in human myeloma resistance to proteasome inhibitors

Lapatinib–induced NF-kappaB activation sensitizes triple-negative breast cancer cells to proteasome inhibitors

Rethinking Proteasome Evolution: Two Novel Bacterial Proteasomes

Inhibition of measles virus replication by proteasome inhibitor Argyrin F constituting a novel virostatic compound

Geranylgeranyl diphosphate synthase inhibitor and proteasome inhibitor combination therapy in multiple myeloma

Downregulation of PA28α induces proteasome remodeling and results in resistance to proteasome inhibitors in multiple myeloma

Repurposing proteasome inhibitors for improved treatment of triple-negative breast cancer

Proteasome inhibitors against amelanotic melanoma

Gastrointestinal toxicities of proteasome inhibitor therapy

Hochschulschrift

Characterisation and optimisation of 20S proteasome inhibitors

Hochschulschrift

Characterisation and optimisation of 20S proteasome inhibitors

Suberoyl bis-hydroxamic acid enhances cytotoxicity induced by proteasome inhibitors in breast cancer cells

A novel role of lysophosphatidic acid (LPA) in human myeloma resistance to proteasome inhibitors

Lapatinib–induced NF-kappaB activation sensitizes triple-negative breast cancer cells to proteasome inhibitors

Rethinking Proteasome Evolution: Two Novel Bacterial Proteasomes

Inhibition of measles virus replication by proteasome inhibitor Argyrin F constituting a novel virostatic compound

Geranylgeranyl diphosphate synthase inhibitor and proteasome inhibitor combination therapy in multiple myeloma

Downregulation of PA28α induces proteasome remodeling and results in resistance to proteasome inhibitors in multiple myeloma

Repurposing proteasome inhibitors for improved treatment of triple-negative breast cancer

Proteasome inhibitors against amelanotic melanoma

Gastrointestinal toxicities of proteasome inhibitor therapy

Hochschulschrift

Characterisation and optimisation of 20S proteasome inhibitors

Hochschulschrift

Characterisation and optimisation of 20S proteasome inhibitors

Suberoyl bis-hydroxamic acid enhances cytotoxicity induced by proteasome inhibitors in breast cancer cells

A novel role of lysophosphatidic acid (LPA) in human myeloma resistance to proteasome inhibitors

Lapatinib–induced NF-kappaB activation sensitizes triple-negative breast cancer cells to proteasome inhibitors

Rethinking Proteasome Evolution: Two Novel Bacterial Proteasomes

Inhibition of measles virus replication by proteasome inhibitor Argyrin F constituting a novel virostatic compound

Geranylgeranyl diphosphate synthase inhibitor and proteasome inhibitor combination therapy in multiple myeloma

Downregulation of PA28α induces proteasome remodeling and results in resistance to proteasome inhibitors in multiple myeloma

Cultural heritage institutions wishing to register will find more information here.

Fields marked * need to be filled in.

Username*

Please enter your username

Email*

Please enter your email address

Please do not fill this field

First name

Last name

Password*

Please enter your password

Confirm password*

Please enter the same password

I have read the terms of use and the privacy policy for the collection of personal data and accept them. *

This field is required.

I would like to subscribe to the newsletter of the Deutsche Digitale Bibliothek. See newsletter subscription info.

Account created

Your "My DDB" account has been successfully created. Before you can log in to your account, you must click the confirmation link in the message we just sent to the email address you provided.

BU-32: a novel proteasome inhibitor for breast cancer

Object Details

References and Relationships

Contributors, Places and Time

Further information

Data provider

Associated

Other Objects (12)

Repurposing proteasome inhibitors for improved treatment of triple-negative breast cancer

Proteasome inhibitors against amelanotic melanoma

Gastrointestinal toxicities of proteasome inhibitor therapy

Characterisation and optimisation of 20S proteasome inhibitors

Characterisation and optimisation of 20S proteasome inhibitors

Suberoyl bis-hydroxamic acid enhances cytotoxicity induced by proteasome inhibitors in breast cancer cells

A novel role of lysophosphatidic acid (LPA) in human myeloma resistance to proteasome inhibitors

Lapatinib–induced NF-kappaB activation sensitizes triple-negative breast cancer cells to proteasome inhibitors

Rethinking Proteasome Evolution: Two Novel Bacterial Proteasomes

Inhibition of measles virus replication by proteasome inhibitor Argyrin F constituting a novel virostatic compound

Geranylgeranyl diphosphate synthase inhibitor and proteasome inhibitor combination therapy in multiple myeloma

Downregulation of PA28α induces proteasome remodeling and results in resistance to proteasome inhibitors in multiple myeloma

Repurposing proteasome inhibitors for improved treatment of triple-negative breast cancer

Proteasome inhibitors against amelanotic melanoma

Gastrointestinal toxicities of proteasome inhibitor therapy

Characterisation and optimisation of 20S proteasome inhibitors

Characterisation and optimisation of 20S proteasome inhibitors

Suberoyl bis-hydroxamic acid enhances cytotoxicity induced by proteasome inhibitors in breast cancer cells

A novel role of lysophosphatidic acid (LPA) in human myeloma resistance to proteasome inhibitors

Lapatinib–induced NF-kappaB activation sensitizes triple-negative breast cancer cells to proteasome inhibitors

Rethinking Proteasome Evolution: Two Novel Bacterial Proteasomes

Inhibition of measles virus replication by proteasome inhibitor Argyrin F constituting a novel virostatic compound

Geranylgeranyl diphosphate synthase inhibitor and proteasome inhibitor combination therapy in multiple myeloma

Downregulation of PA28α induces proteasome remodeling and results in resistance to proteasome inhibitors in multiple myeloma

Repurposing proteasome inhibitors for improved treatment of triple-negative breast cancer

Proteasome inhibitors against amelanotic melanoma

Gastrointestinal toxicities of proteasome inhibitor therapy

Characterisation and optimisation of 20S proteasome inhibitors

Characterisation and optimisation of 20S proteasome inhibitors

Suberoyl bis-hydroxamic acid enhances cytotoxicity induced by proteasome inhibitors in breast cancer cells

A novel role of lysophosphatidic acid (LPA) in human myeloma resistance to proteasome inhibitors

Lapatinib–induced NF-kappaB activation sensitizes triple-negative breast cancer cells to proteasome inhibitors

Rethinking Proteasome Evolution: Two Novel Bacterial Proteasomes

Inhibition of measles virus replication by proteasome inhibitor Argyrin F constituting a novel virostatic compound

Geranylgeranyl diphosphate synthase inhibitor and proteasome inhibitor combination therapy in multiple myeloma

Downregulation of PA28α induces proteasome remodeling and results in resistance to proteasome inhibitors in multiple myeloma

Related objects

Reset password